Real-World Selection of Patients for Allogeneic HCT at a Single Centre: Lack of a Suitable Donor and Other Reasons for Not Proceeding
Current Oncology · 2025
DOI: 10.3390/curroncol32090483 ↗Kurz gefasst
Fachartikel in der Zeitschrift Current Oncology, 2025. Verfasst von Madeline Monaghan und 12 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, University of Ottawa, Ottawa, ON K1H 8M5, Canada. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Tissue Donors, Patient Selection. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cancer Care Ontario (Ministry of Health, Ontario), Faculty of Medicine, University of Ottawa.
Abstract (Originalsprache)
The reasons why patients cannot proceed with HCT, including cases where no suitable donor is identified, remain poorly described. We reviewed all referrals for allogeneic HCT to our programme between 1 January 2019 and 31 December 2023. Of 880 patients referred for allogeneic HCT, 494 (61.8%) proceeded to transplant (mean 52 ± 14.8 years, 61.5% male) using HLA-matched unrelated (64.2%) or related (19.4%) donors and HLA-mismatched (13%) or haploidentical (3%) donors. Of patients that did not proceed with HCT (386, 38.2%), disease-related causes (54.2%), patient preference (15.8%), and significant patient comorbidity (11.4%) were the most common reasons. Eleven patients (2.9% of transplants that did not proceed; 1.3% of all referrals) lacked a suitable donor and had HLA phenotypes most associated with Caucasian (six patients, 55%), First Nations, Inuit or Metis (two patients, 18%), Black African, Caribbean or African American (one patient, 9%), Asian or Pacific Islander (9%), or unknown ethnicity (one patient, 9%). Very few patients were unable to proceed with transplant due to lack of a suitable donor; however, those cases are overrepresented by non-Caucasian ethnicity relative to the population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Faculty of Medicine, University of Ottawa, Ottawa, ON K1H 8M5, Canada.
- Cancer Research Program, Ottawa Hospital Research Institute, Ottawa, ON K1H 8L6, Canada.
- Transplantation & Cellular Therapy Program, Department of Medicine (Hematology), The Ottawa Hospital, Ottawa, ON K1H 8L6, Canada.
ORCID-Profile: Harold Atkins, Michael Kennah, David S Allan
Förderung
- Cancer Care Ontario (Ministry of Health, Ontario)
- Faculty of Medicine, University of Ottawa
Zitieren
APA
Monaghan, M., Duong, A., Abrol, K., Doan, T., Cieniak, C., Atkins, H., Kekre, N., Masurekar, A., Vasudevan Nampoothiri, R., Thyagu, S., Bredeson, C. N., Kennah, M., & Allan, D. S. (2025). Real-World Selection of Patients for Allogeneic HCT at a Single Centre: Lack of a Suitable Donor and Other Reasons for Not Proceeding. Current Oncology. https://doi.org/10.3390/curroncol32090483
Vancouver
Monaghan M, Duong A, Abrol K, Doan T, Cieniak C, Atkins H, et al. Real-World Selection of Patients for Allogeneic HCT at a Single Centre: Lack of a Suitable Donor and Other Reasons for Not Proceeding. Current Oncology. 2025. doi:10.3390/curroncol32090483
BibTeX
@article{Monaghan2025,
author = {Monaghan, Madeline and Duong, An and Abrol, Kalina and Doan, Trang and Cieniak, Carolina and Atkins, Harold and Kekre, Natasha and Masurekar, Ashish and Vasudevan Nampoothiri, Ram and Thyagu, Santhosh and Bredeson, Christopher N and Kennah, Michael and Allan, David S},
title = {Real-World Selection of Patients for Allogeneic HCT at a Single Centre: Lack of a Suitable Donor and Other Reasons for Not Proceeding},
journal = {Current Oncology},
year = {2025},
doi = {10.3390/curroncol32090483}
}
EUVIMED